InpharmD™
Evidence Based Medicine presented by InpharmD™
We take the most popularly asked clinical questions monthly and create a class around the corresponding evidence. Our EBM podcast will offer a glimpse into the evidence covered, and listeners can follow up with our CE if interested in more information.
Be sure to visit the podcast's website and support the creator: inpharmd.libsyn.com
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Anaphylaxis after Pfizer Vaccine 26.02.2021 6:51
Early data suggests the incidence of true anaphylaxis to the Pfizer-BioNTech COVID-19 vaccine is rare (11.1 cases per million vaccine doses). Anaphylaxis is more common in women and persons with a history of allergies, and symptoms typically appear within 30 minutes of injection.
Association of Psychiatric Disorders and COVID-19 19.02.2021 5:58
A retrospective, observational, cohort study done to assess whether a diagnosis of a schizophrenia spectrum disorder, mood disorder, or anxiety disorder is associated with mortality in patients with COVID-19.
Preliminary Data on Johnson and Johnson Vaccine 08.02.2021 8:08
A randomized, multicenter, double-blind, placebo-controlled, phase 1/2a clinical trial to evaluate the safety, reactogenicity, and immunogenicity of Ad26.COV2.S - a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein
Clinical Characteristics of COVID-19 in Hematopoietic Stem-Cell Transplantation Recipients 01.02.2021 8:16
An observational cohort study performed to describe characteristics and outcomes of hematopoietic stem-cell transplantation (HSCT) recipients after developing COVID-19
Continuation versus discontinuation of RAAS inhibitors in hospitalized patients with COVID-19 25.01.2021 5:34
A prospective, randomized, open-label trial performed to evaluate whether continuation of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is beneficial or harmful in patients who are admitted to hospital with COVID-19.
Comparative Differences Between COVID-19 and Seasonal Influenza 19.01.2021 5:29
A cohort study done to comparatively examine differences in risk of clinical manifestations and death among people admitted to hospital with coronavirus disease 2019 (COVID-19) and seasonal influenza.
Efficacy and Safety of the Moderna mRNA-1273 SARS-CoV-2 Vaccine to Prevent COVID-19 12.01.2021 9:31
A phase 3 randomized, stratified, observer-blinded, placebo-controlled trial to to assess the safety and efficacy of the mRNA-1273 vaccine in preventing SARS-CoV-2 infection.
Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19 (ACTT-2) 04.01.2021 6:37
A randomized, multicenter, adaptive, double-blind, placebo-controlled trial to evaluate whether the combination of baricitinib plus remdesivir was superior to remdesivir alone.
Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic 28.12.2020 6:09
A comparative study done to evaluate the fitted filtration efficiency (FFE) of various consumer-grade and improvised face masks, as well as several popular modifications of medical procedure masks that are intended to improve mask fit or comfort.
Simultaneous COVID-19 in Homozygous Twins 22.12.2020 6:31
A case report describing two monozygotic twins with different clinical courses, despite having the same environment and genomic factors.
Adjusted BMI and risk of death due to COVID-19 18.12.2020 6:01
A retrospective, cohort study conducted to determine the adjusted effect of body mass index (BMI), associated comorbidities, time, neighborhood-level sociodemographic factors, and other factors on risk for death due to COVID-19
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomized, double-blind, placebo-controlled, phase 2 trial 10.12.2020 6:58
A randomzied, double-blind, placebo-controlled, multicenter, phase 2, pilot trial conducted to determine whether inhaled SNG001 (recombinant interferon beta-1a) has the potential to reduce the severity of lower respiratory tract illness and accelerate recovery in patients diagnosed with COVID-19.
Bamlanivimab - SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 27.11.2020 8:05
The purpose of this study was to evaluate the efficacy and safety of LY-CoV555 (bamlanivimab) in patients with recently diagnosed mild or moderate COVID-19 in the outpatient setting
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates 19.11.2020 7:34
What does the evidence says on the safety and immunogenicity of pfizer's potential vaccine - BNT162b2 - as compared to other candidates?
Levels of Severity of Depressive Symptoms Among At-Risk Groups During COVID-19 12.11.2020 6:09
A cohort study examining levels of severity of depressive symptoms over time among individuals with high risk in the UK during the COVID-19 pandemic
Efficacy of Tocilizumab in Patients Hospitalized with COVID-19 06.11.2020 5:53
A randomized, double-blind, placebo-controlled trial conducted to assess if early intervention with interleukin-6 receptor blockade might limit COVID-19 progression to hypoxemic respiratory failure or death, reduce the risk of clinical worsening, and decrease the duration of supplemental oxygen use.
Genomic evidence for reinfection with SARS-CoV-2: a case study 27.10.2020 6:34
A 25-year old male patient was infected on two separate occasions, with the second infection being symptomatically more severe than the first. Genomic analysis showed the two viral agents were genetically distinct.
Remdesivir for the Treatment of Covid-19 — Final Report 22.10.2020 7:11
The objective of this study was to evaluate the clinical efficacy and safety of remdesivir among hospitalized adults with laboratory-confirmed COVID-19.
Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of COVID-19 in SARS-CoV-2 infected male patients: a cohort study 16.10.2020 6:39
The objective of the cohort study was to investigate the effect of serum testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 in SARS-CoV-2 infected male patients
Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry 08.10.2020 6:37
The objective of this study was to use the Extracorporeal Life Support Organization (ELSO) Registry to report the epidemiology, treatment, outcomes, and hospital characteristics of patients receiving extracorporeal membrane oxygenation (ECMO)with a confirmed diagnosis of Corona Virus Disease 2019 (COVID-19).
Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among US Veterans With SARS-CoV-2 Infection 02.10.2020 7:40
A study to determine the risk of hospitalization, mechanical ventilation, and death associated with infection; and to identify characteristics independently associated with these outcomes in patients who tested positive for severe acute respiratory syndrome coronavirus 2. Read more: inpharmd.com/covid
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine 26.09.2020 8:53
What does the evidence say on the safety and immunogenicity of the new Novavax vaccine for the SARS-CoV-2 infection?
Cell Phone Activity in Categories of Places and Associations With Growth in Cases of COVID-19 in the US 17.09.2020 6:28
Is cell phone location data associated with the rate of change in new COVID-19 cases by county across the US? Tune in to what the evidence say.
Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19 11.09.2020 8:28
An open-label, non-randomized, single-arm, Expanded Access Program (EAP) trial conducted to explore potential signals of efficacy of COVID-19 convalescent plasma. Read more here: inpharmd.com/covid
Ruxolitinib in Severe, COVID-19 Patients: A Randomized Phase-II Trial 02.09.2020 5:53
A prospective, multi-center, single-blind, randomized controlled phase II trial assessing the efficacy and safety of ruxolitinib in hospitalized COVID-19 patients
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.